Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and primary immunodeficiencies - Novel tool for diagnostics and patient follow-up

Autoimmunity Reviews

Volumn 12, Issue 10, 2013, Pages 967-971

  Osnes, Liv T ^a   Nakken, Britt ^a   Bodolay, Edit ^b   Szodoray, Peter ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Autoimmune diseases; Immunodeficiencies; Immunoregulatory abnormalities; Regulatory T cells; Soluble, intracellular cytokines; Th17 cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CONNECTIVE TISSUE DISEASE; CYTOKINE PRODUCTION; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIGEORGE SYNDROME; FOLLOW UP; HELPER CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; LYMPHOCYTE SUBPOPULATION; MIXED CONNECTIVE TISSUE DISEASE; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SJOEGREN SYNDROME; SYSTEMIC SCLEROSIS; TH17 CELL;

AIRE; ALIPOPROTEIN A1; APOA1; AUTOIMMUNE DISEASES; AUTOIMMUNE REGULATOR; BREG; CFS; CHRONIC FATIGUE SYNDROME; COMMON VARIABLE IMMUNODEFICIENCY; CVID; ECP; EPO; ERYTHROPOIETIN; EXTRACORPOREAL PHOTOCHEMOTHERAPY; G-CSF; GRANULOCYTE COLONY-STIMULATING FACTOR; HEPATOCYTE GROWTH FACTOR; HGF; IFN; IL; IL-1RA; IMMUNODEFICIENCIES; IMMUNODYSREGULATION POLYENDOCRINOPATHY ENTEROPATHY X-LINKED SYNDROME; IMMUNOREGULATORY ABNORMALITIES; INDUCED REGULATORY T CELL; INTERFERON; INTERLEUKIN; INTERLEUKIN-1 RECEPTOR ALPHA; IPEX; ITREG; MCTD; ME; MIXED CONNECTIVE TISSUE DISEASE; MYALGIC ENCEPHALITIS; NATURAL KILLER CELL; NATURAL KILLER T CELL; NATURAL REGULATORY T CELL; NK; NKT; NTREG; PID; PM/DM; POLYMYOSITIS/DERMATOMYOSITIS; PRIMARY IMMUNODEFICIENCY; RA; RAG; RECOMBINATION ACTIVATING GENES; REGULATORY B CELL; REGULATORY T CELL; REGULATORY T CELLS; RHEUMATOID ARTHRITIS; SCID; SENSORINEURAL HEARING LOSS; SEVERE COMBINED IMMUNODEFICIENCY; SJÖGREN'S SYNDROME; SLE; SNHL; SOLUBLE, INTRACELLULAR CYTOKINES; SS; SSC; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T-CYTOTOXIC CELL; T-HELPER CELL; TC; TH; TH17 CELLS; THROMBOPOIETIN; TNF; TPO; TREG; TUMOR NECROSIS FACTOR; U1 RIBONUCLEOPROTEIN; U1RNP; UCTD; UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE;

AUTOIMMUNE DISEASES; B-LYMPHOCYTES, REGULATORY; BIOLOGICAL MARKERS; CYTOKINES; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; T-LYMPHOCYTES, REGULATORY;

EID: 84880575987     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.02.003     Document Type: Review

References (66)

1. O'Garra A., Arai N. The molecular basis of T helper 1 and T helper2 cell differentiation. Trends Cell Biol 2000, 10:542-550.
2. H2 hypothesis of T-cell-mediated tissue damage. Nat Med 2007, 13:139-145.
3. Toda A., Piccirillo C.A. Development and function of naturally occurring CD4+CD25+ regulatory cells. J Leukoc Biol 2006, 80:458-470.
4. Nakken B., Munthe L.A., Konttinen Y.T., Sandberg A.K., Szekanecz Z., Alex P., et al. B-cells and their targeting in rheumatoid arthritis - current concepts and future perspectives. Autoimmun Rev 2011, 11:28-34.
5. Baráth S., Sipka S., Aleksza M., Szegedi A., Szodoray P., Végh J., et al. Regulatory T-cells in peripheral blood of patients with mixed connective tissue disease. Scand J Rheumatol 2006, 35:300-304.
6. Dejaco C., Duftner C., Grubeck-Loebenstein B., Schirmer M. Imbalance of regulatory T-cells in human autoimmune diseases. Immunol Today 2006, 117:289-300.
7. Alarcon G.S. Unclassified or undifferentiated connective tissue disease. Baillieres Best Pract Res Clin Rheumatol 2000, 14:125-137.
8. LeRoy E.C., Maricq H.R., Kahaleh M.B. Undifferentiated connective tissue syndromes. Arthritis Rheum 1980, 23:341-343.
9. Mosca M., Tani C., Neri C., Baldini C., Bormardieri S. Undifferentiated connective tissue disease. Autoimmun Rev 2000, 6:1-4.
10. Williams H.J., Alarcón G.S., Neuner R., Steen V.D., Bulpitt K., Clegg D.O., et al. Early undifferentiated connective tissue disease. V. An inception cohort 5years later: disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases. J Rheumatol 1998, 25:261-268.
11. Williams H.J., Alarcon G.S., Joks R., Steen V.D., Bulpitt K., Clegg D.O., et al. Early undifferentiated connective tissue disease (CTD) VI: an inception cohort after 10years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol 1999, 26:816-825.
12. Szodoray P., Nakken B., Barath S., Gaal J., Aleksza M., Zeher M., et al. Progressive divergent shifts in natural and induced T-regulatory cells signify the transition from undifferentiated to definitive connective tissue disease. Int Immunol 2008, 20:971-979.
13. Zold E., Szodoray P., Kappelmayer J., Gaal J., Csathy L., Barath S., et al. Impaired regulatory T-cell homeostasis due to vitamin D deficiency in undifferentiated connective tissue disease. Scand J Rheumatol 2010, 39:490-497.
14. Zold E., Szodoray P., Nakken B., Barath S., Kappelmayer J., Csathy L., et al. Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease. Autoimmun Rev 2011, 10:155-162.
15. Zeher M. Sjögren's syndrome. Research signpost 2006, 1-7. Transworld Research Network, Kerala, India. M. Zeher, P. Szodoray (Eds.).
16. Szodoray P., Nakken B. Selected molecular aspects behind the clinical picture of Sjögren's syndrome. Research signpost 2006, 27-49. Transworld Research Network, Kerala, India. M. Zeher, P. Szodoray (Eds.).
17. Szodoray P., Alex P., Brun J.G., Centola M., Jonsson R. Circulating cytokines in primary Sjögren's syndrome determined by a multiplex cytokine array system. Scand J Immunol 2004, 59:592-599.
18. Garcíc-Carrasco M., Font J., Filella X., Cervera R., Ramos-Casals M., Sisó A., et al. Circulating levels of Th1/Th2 cytokines in patients with primary Sjögren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 2001, 19:411-415.
19. Yao Y., Liu Z., Jallal B., Shen N., Rönnblom L. Type I interferons in Sjögren's syndrome. Autoimmun Rev 2013, 12(5):558-566.
20. Jonsson R., Moen K., Vestrheim D., Szodoray P. Current issues in Sjögren's syndrome. Oral Dis 2002, 8:130-140.
21. Szodoray P., Gal I., Barath S., Aleksza M., Horvath I.F., Gergely P., et al. Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines. Scand J Rheumatol 2008, 37:205-212.
22. Szodoray P., Papp G., Horvath I.F., Barath S., Sipka S., Nakken B., et al. Cells with regulatory function of the innate and adaptive immune system in primary Sjögren's syndrome. Clin Exp Immunol 2009, 157:343-349.
23. Szodoray P., Alex P., Jonsson M.V., Knowlton N., Dozmorov I., Nakken B., et al. Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 2005, 117:168-176.
24. Szodoray P., Horvath I.F., Papp G., Barath S., Gyimesi E., Csathy L., et al. The immunoregulatory role of vitamins A, D and E in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2010, 49:211-217.
25. LeRoy E.C., Medsger T.A. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001, 28:1573-1576.
26. Lei W., Luo Y., Lei W., Luo Y., Yan K., Zhao S. Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol 2009, 38:369-374.
27. Horikawa M., Hasegawa M., Komura K., Hayakawa I., Yanaba K., Matsushita T. Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity. J Invest Dermatol 2005, 125:731-737.
28. Riccieri V., Parisi G., Spadaro A., Scrivo R., Barone F., Moretti T. Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis. J Rheumatol 2005, 32:283-286.
29. Slobodin G., Ahmad M.S., Rosner I., Peri R., Rozenbaum M., Kessel A. Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 2010, 261:77-80.
30. Banica L., Besliu A., Pistol G., Stavaru C., Ionescu R., Forsea A.M. Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 2009, 42:41-49.
31. Murata M., Fujimoto M., Matsushita T., Hamaguchi Y., Hasegawa M., Takehara K. Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?. J Dermatol Sci 2008, 50:240-242.
32. Deleuran B., Abraham D.J. Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheumatol 2007, 3:682-683.
33. Sakkas L.I., Platsoucas C.D. Is systemic sclerosis an antigen-driven T cell disease?. Arthritis Rheum 2004, 50:1721-1733.
34. Papp G., Horvath I.F., Barath S., Gyimesi E., Sipka S., Szodoray P., et al. Altered T-cell and regulatory cell repertoire in patients with diffuse cutaneous systemic sclerosis. Scand J Rheumatol 2011, 40:205-210.
35. Papp G., Horvath I.F., Barath S., Gyimesi E., Vegh J., Szodoray P., et al. Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis. Clin Immunol 2012, 142:150-159.
36. Papp G., Barath S., Szegedi A., Szodoray P., Zeher M. The effects of extracorporeal photochemotherapy on T cell activation and regulatory mechanisms in patients with systemic sclerosis. Clin Rheumatol 2012, 31:1293-1299.
37. Sharp G.C., Irvin W.S., Tan E.M., Gould R.G., Holman H.R. Mixed connective tissue disease - an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen. Am J Med 1972, 52:148-159.
38. Sharp G.C. Diagnostic criteria for classification of MCTD. Mixed connective tissue disease and antinuclear antibodies 1987, 23-33. Elsevier Science Publishers BV, Amsterdam. R. Kasukawa, G.C. Sharp (Eds.).
39. Kasukawa R., Tojo T., Miyawaki S. Preliminary diagnostic criteria for classification of mixed connective tissue disease. Mixed connective tissue disease and antinuclear antibodies 1987, 41-47. Elsevier Science Publishers BV, Amsterdam. R. Kasukawa, G.C. Sharp (Eds.).
40. Hameenkorpi R., Ruuska P., Forsberg S., Tiilikainen R., Makitalo R., Hakula M. More evidence of distinctive features of mixed connective tissue disease. Scand J Rheumatol 1993, 22:63-68.
41. Smolen J.S., Steiner G. Mixed connective tissue disease: to be or not to be?. Arthritis Rheum 1998, 41:768-777.
42. Hoffman R.W., Greidinger E.L. Mixed connective tissue disease. Curr Opin Rheumatol 2000, 12:386-390.
43. Maddison P.J. Mixed connective tissue disease: overlap syndromes. Baillieres Best Pract Res Clin Rheumatol 2000, 14:111-124.
44. Burdt M.A., Hoffman R.W., Deutscher S.L., Wang G.S., Johnson J.C., Sharp G.C. Long-term outcome in mixed connective tissue disease. Arthritis Rheum 1999, 42:899-909.
45. Bodolay E., Aleksza M., Antal-Szalmás P., Végh J., Szodoray P., Soltész P., et al. Serum cytokine levels and type 1 and type 2 intracellular T cell cytokine profiles in mixed connective tissue disease. J Rheumatol 2002, 29:2136-2142.
46. Baráth S., Sipka S., Aleksza M., Szegedi A., Szodoray P., Végh J., et al. Regulatory T cells in peripheral blood of patients with mixed connective tissue disease. Scand J Rheumatol 2006, 35:300-304.
47. Hajas A., Szodoray P., Barath S., Sipka S., Rezes S., Zeher M., et al. Sensorineural hearing loss in patients with mixed connective tissue disease: immunological markers and cytokine levels. J Rheumatol 2009, 36:1930-1936.
48. Hajas A., Sandor J., Csathy L., Csipo I., Barath S., Paragh G., et al. Vitamin D insufficiency in a large MCTD population. Autoimmun Rev 2011, 10:317-324.
49. Belkaid Y., Rouse B.T. Natural regulatory T cells in infectious disease. Nat Immunol 2005, 6:353-360.
50. Moraes-Vasconcelos D., Costa-Carvalho B.T., Torgerson T.R., Ochs H.D. Primary immune deficiency disorders presenting as autoimmune diseases: IPEX and APECED. J Clin Immunol 2008, 28(Suppl. 1):S11-S19.
51. Gambineri E., Torgerson T.R. Genetic disorders with immune dysregulation. Cell Mol Life Sci 2012, 69:49-58.
52. Torgerson T.R. Immunodeficiency diseases with rheumatic manifestations. Pediatr Clin North Am 2012, 59:493-507.
53. McLean-Tooke A., Barge D., Spickett G.P., Gennery A.R. Flow cytometric analysis of TCR Vbeta repertoire in patients with 22q11.2 deletion syndrome. Scand J Immunol 2011, 73:577-585.
54. Caudy A.A., Reddy S.T., Chatila T., Atkinson J.P., Verbsky J.W. CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol 2007, 119:482-487.
55. Adriani M., Aoki J., Horai R., Thornton A.M., Konno A., Kirby M., et al. Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. Clin Immunol 2007, 124:41-48.
56. Kanai T., Jenks J., Nadeau K.C. The STAT5b pathway defect and autoimmunity. Front Immunol 2012, 3:234.
57. Ochs H.D., Oukka M., Torgerson T.R. TH17 cells and regulatory T cells in primary immunodeficiency diseases. J Allergy Clin Immunol 2009, 123:977-983.
58. Takezaki S., Yamada M., Kato M., Park M.J., Maruyama K., Yamazaki Y., et al. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain. J Immunol 2012, 189:1521-1526.
59. Puel A., Doffinger R., Natividad A., Chrabieh M., Barcenas-Morales G., Picard C., et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010, 207:291-297.
60. Chaturvedi V., Collison L.W., Guy C.S., Workman C.J., Vignali D.A. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011, 186:6661-6666.
61. Brenu E.W., Ashton K.J., van Driel M., Staines D.R., Peterson D., Atkinson G.M., et al. Cytotoxic lymphocyte microRNAs as prospective biomarkers for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Affect Disord 2012, 141:261-269.
62. Brenu E.W., van Driel M.L., Staines D.R., Ashton K.J., Hardcastle S.L., Keane J., et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Transl Med 2012, 10:88.
63. Brenu E.W., van Driel M.L., Staines D.R., Ashton K.J., Ramos S.B., Keane J., et al. Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Transl Med 2011, 9:81.
64. Baraut J., Michel L., Verrecchia F., Farge D. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010, 10:65-73.
65. Dong W., Zhu P. Functional niche of inflamed synovium for Th17-cell expansion and activation in rheumatoid arthritis: implication to clinical therapeutics. Autoimmun Rev 2012, 11:844-851.
66. Semerano L., Assier E., Boissier M.C. Anti-cytokine vaccination: a new biotherapy of autoimmunity?. Autoimmun Rev 2012, 11:785-786.